Food and Drug Law Institute

Food and Drug Law Institute
Name	Food and Drug Law Institute
Abbreviation	FDLI
Formation	1971
Type	Nonprofit organization
Headquarters	Washington, D.C.
Region served	United States, International
Leader title	President and CEO

Contents

Food and Drug Law Institute

The Food and Drug Law Institute is a nonprofit membership association that convenes professionals involved with Food and Drug Administration, United States Department of Health and Human Services, European Medicines Agency, World Health Organization, National Institutes of Health, Centers for Disease Control and Prevention, and international regulatory authorities to address legal, regulatory, and policy issues affecting Federal Food, Drug, and Cosmetic Act, Public Health Service Act, and associated statutes. Founded in 1971 during a period of expanding regulatory oversight following high-profile product safety controversies such as the Thalidomide crisis and the enactment of the Kefauver Harris Amendment, the Institute serves as a hub for practitioners from law firms like Covington & Burling, Hogan Lovells, Ropes & Gray, corporate counsel at Pfizer, Johnson & Johnson, GlaxoSmithKline, and agencies including Office of Inspector General (United States Department of Health and Human Services).

History

The organization's origins reflect intersections among key episodes in regulatory history: the aftermath of Thalidomide and the passage of the Kefauver Harris Amendment influenced early convenings that included stakeholders from United States Congress, Food and Drug Administration, and academic centers such as Harvard Law School, Georgetown University Law Center, Columbia Law School, and University of Pennsylvania Carey Law School. During the 1980s and 1990s the Institute expanded programming tied to landmark legal developments including Prescription Drug Marketing Act, the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act), and rulings from the United States Supreme Court addressing administrative law and preemption. In the 21st century FDLI's growth paralleled initiatives from European Medicines Agency, Pharmaceutical Research and Manufacturers of America, and global health responses coordinated with World Health Organization and Gavi, the Vaccine Alliance.

Governance includes a board drawn from law firms, corporations, and government agencies including former officials from Food and Drug Administration and United States Department of Health and Human Services. Committees and task forces mirror topical divisions found at European Medicines Agency and International Pharmaceutical Regulators Forum with subject-matter working groups on pharmacovigilance, clinical trials policy linked to Food and Drug Administration Modernization Act of 1997, and drug safety frameworks shaped by cases litigated in the United States Court of Appeals for the Federal Circuit. Operational functions reflect nonprofit models used by American Bar Association, National Association of Attorneys General, and international NGOs like Bill & Melinda Gates Foundation in convening multidisciplinary advisory councils.

FDLI organizes conferences, symposia, and workshops patterned after large-scale gatherings such as those hosted by BIO (trade association), DIA (Drug Information Association), American Indian Science and Engineering Society, and academic conferences at Johns Hopkins Bloomberg School of Public Health. Signature events draw regulators from Food and Drug Administration district offices, counsel from Skadden, Arps, Slate, Meagher & Flom, corporate executives from Merck & Co., and representatives of Pharmacopeia organizations. Programs include training on Good Manufacturing Practice, compliance modules reflecting 21st Century Cures Act, and sessions on emergency response coordination with Federal Emergency Management Agency and Centers for Disease Control and Prevention during public health crises such as the COVID-19 pandemic.

The Institute issues scholarly and practitioner-oriented materials comparable to journals published by American Bar Association and reports similar to those from National Academies Press. Publications include analyses of regulatory decisions from Food and Drug Administration Advisory Committees, summaries of litigation before the United States Supreme Court and federal appellate courts, and commentaries on policy instruments like the Orphan Drug Act and the Affordable Care Act. FDLI convenes investigators and authors affiliated with Yale Law School, Stanford Law School, New York University School of Law, and policy centers such as Brookings Institution and Institute for Clinical and Economic Review.

While primarily educational, the Institute engages in policy dialogue with members of United States Congress, staff at Food and Drug Administration, and international delegations to World Health Assembly. It facilitates consensus-building among industry associations including Pharmaceutical Research and Manufacturers of America and advocacy groups like PatientsLikeMe and National Health Council. Through white papers and expert panels, FDLI contributes to debates on patent linkage exemplified by Hatch-Waxman Act litigation, regulatory reform efforts tied to the 21st Century Cures Act, and global harmonization initiatives involving International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.

Membership encompasses attorneys, regulatory affairs professionals, scientists from Centers for Disease Control and Prevention, compliance officers from AbbVie, and academics from University of California, Berkeley School of Law. Professional development offerings mirror continuing legal education programs delivered by American Bar Association and industry certifications associated with Regulatory Affairs Professionals Society. Career-focused services include networking with in-house counsel at Novartis, placement resources similar to those at Association of American Medical Colleges, and mentorship programs connecting early-career professionals with leaders who have served at Food and Drug Administration and European Medicines Agency.

Category:Organizations established in 1971